EUVIMEDOpdag EUVIMED
Crossref

SIRT1 promotes doxorubicin‐induced breast cancer drug resistance and tumor angiogenesis via regulating GSH‐mediated redox homeostasis

Shashikanta Sahoo, Sunita Kumari, Sriravali Pulipaka, Yogesh Chandra, Srigiridhar Kotamraju iD

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23809 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2024. Written by Shashikanta Sahoo and 4 co-authors. Institution: Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, India. Major MEDLINE topics: Sirtuin 1, Doxorubicin, Drug Resistance, Neoplasm, Breast Neoplasms. Cited 18 times so far (Crossref); 36 references. Funded by: Council of Scientific and Industrial Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Sirtuin 1 (SIRT1), a member of histone deacetylase III family, plays a pivotal role in mediating chemoresistance in several cancers, including breast cancer. However, the molecular mechanism by which the deregulated SIRT1 promotes doxorubicin (Dox) resistance is still elusive. Here, we showed that the cell proliferation rates and invasive properties of MDA‐MB‐231 breast cancer cells were increased from low‐ to high‐Dox‐resistant cells. In agreement, severe combined immunodeficiency disease (SCID) mice bearing labeled MDA‐MB‐231 high Dox‐Res cells showed significantly higher tumor growth, angiogenesis, and metastatic ability than parental MDA‐MB‐231 cells. Interestingly, the levels of SIRT1 and glutathione (GSH) were positively correlated with the degree of Dox‐resistance. Dox‐induced SIRT1 promoted NRF2 nuclear translocation with an accompanying increase in the antioxidant response element promotor activity and GSH levels. In contrast, inhibition of SIRT1 by EX527 greatly reversed these events. More so, Dox‐resistance‐induced pro‐proliferative, proangiogenic, and invasive effects were obviated with depletion of either SIRT1 or GSH. Together, Dox‐induced SIRT1 promotes dysregulation of redox homeostasis leading to breast cancer chemoresistance, tumor aggressiveness, angiogenesis, and metastasis.

Subjects

MeSH terms (MEDLINE)

Sirtuin 1DoxorubicinDrug Resistance, NeoplasmBreast NeoplasmsNeovascularization, PathologicHomeostasisMice, SCIDGlutathioneOxidation-ReductionCell ProliferationAnimalsHumansFemaleMiceCell Line, TumorXenograft Model Antitumor AssaysAntibiotics, AntineoplasticGene Expression Regulation, NeoplasticNF-E2-Related Factor 2Angiogenesis

Author keywords

GSHSIRT1breast cancerdoxorubicindrug resistance

Substances

Sirtuin 1DoxorubicinSIRT1 protein, humanGlutathioneAntibiotics, AntineoplasticNF-E2-Related Factor 2

Authors and institutions

  • Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, India.

ORCID profiles: Srigiridhar Kotamraju

Funding

  • Council of Scientific and Industrial Research

Cite

APA

Sahoo, S., Kumari, S., Pulipaka, S., Chandra, Y., & Kotamraju, S. (2024). SIRT1 promotes doxorubicin‐induced breast cancer drug resistance and tumor angiogenesis via regulating GSH‐mediated redox homeostasis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23809

Vancouver

Sahoo S, Kumari S, Pulipaka S, Chandra Y, Kotamraju S. SIRT1 promotes doxorubicin‐induced breast cancer drug resistance and tumor angiogenesis via regulating GSH‐mediated redox homeostasis. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23809

BibTeX
@article{Sahoo2024,
  author = {Sahoo, Shashikanta and Kumari, Sunita and Pulipaka, Sriravali and Chandra, Yogesh and Kotamraju, Srigiridhar},
  title = {SIRT1 promotes doxorubicin‐induced breast cancer drug resistance and tumor angiogenesis via regulating GSH‐mediated redox homeostasis},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23809}
}
Start for free →